With a passion to help patients defeat their cancer, Forty Seven is committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. On March 2nd, 2020, Gilead announced it will acquire Forty Seven for $4.9 billion.
Total raised: $156M
Investors 2
Date | Name | Website |
- | Lightspeed... | lsvp.com |
- | GV | gv.com |
Funding Rounds 3
Date | Series | Amount | Investors | Deal News |
07.08.2019 | - | $6M | - | finsmes.co... |
18.10.2017 | Series B | $75M | - | finsmes.co... |
25.02.2016 | Series A | $75M | - | fiercebiot... |
Mentions in press and media 20
Date | Title | Description | Category | Author | Source |
21.03.2020 | Gilead To ... | Gilead Sciences, Inc. (Nasdaq:... | USA | - | finsmes.co... |
02.03.2020 | Gilead to ... | Forty Seven’s lead product can... | - | - | medcitynew... |
12.02.2020 | ALX Oncolo... | The company plans to invest th... | - | - | medcitynew... |
07.08.2019 | Forty Seve... | Forty Seven, Inc., a Menlo Par... | USA | - | finsmes.co... |
26.03.2019 | Arch Oncol... | The financing was led by a new... | - | - | medcitynew... |
28.06.2018 | Term Sheet... | LYFTED Good morning, Term She... | - | - | fortune.co... |
19.06.2018 | Term Sheet... | MORE DATA, FEWER HUMANS What’... | - | - | fortune.co... |
20.10.2017 | Term Sheet... | TRENDY IPO Happy Friday, Term... | - | - | fortune.co... |
18.10.2017 | Forty Seve... | Forty Seven has raised $75 mil... | Biotech | - | fiercebiot... |
18.10.2017 | Forty Seve... | MENLO PARK, CA, Clinical-sta... | - | - | vcnewsdail... |
Show more